{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T16:08:08Z","timestamp":1747066088708,"version":"3.32.0"},"reference-count":87,"publisher":"FapUNIFESP (SciELO)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p>Hiperlipidemia combinada familiar (HCF) \u00e9 a forma mais comum de hiperlipidemia familial e se caracteriza por resist\u00eancia \u00e0 insulina, n\u00edveis baixos de HDL-C, n\u00edveis altos de triglic\u00e9rides (TGC) e colesterol total associados a v\u00e1rios fen\u00f3tipos dentro da mesma fam\u00edlia. HCF associa-se, tamb\u00e9m, a um alto risco cardiovascular (RCV), e os n\u00edveis-alvo de tratamento das anormalidades lip\u00eddicas t\u00eam se modificado recentemente. Reduzir os n\u00edveis de LDL-C e n\u00e3o HDL-C devem ser os alvos da terapia. N\u00edveis de LDL-C abaixo de 70 mg\/dl t\u00eam se mostrado ben\u00e9ficos na RCV em pacientes de alto risco. V\u00e1rias estatinas com diferentes pot\u00eancias e intera\u00e7\u00f5es medicamentosas est\u00e3o dispon\u00edveis no mercado. A terapia combinada de estatinas com seq\u00fcestradores de \u00e1cidos biliares ou ezetimiba pode ser necess\u00e1ria para se alcan\u00e7ar os valores-alvo de LDL-C estabelecidos pelas diretrizes. N\u00edveis altos de TGC e baixos de HDL-C devem ser tamb\u00e9m considerados no tratamento, e freq\u00fcentemente somente o uso das estatinas se mostra insuficiente para normaliz\u00e1-los. A combina\u00e7\u00e3o de estatinas com fibratos pode auxiliar para reduzir os n\u00edveis de colesterol e aumentar os de HDL-C, mas est\u00e1 associada \u00e0 maior freq\u00fc\u00eancia de miopatia e toxicidade hep\u00e1tica. Assim, a avalia\u00e7\u00e3o cuidadosa dos riscos e benef\u00edcios da terapia \u00e9 recomend\u00e1vel. A associa\u00e7\u00e3o de estatina e niacina parece ser \u00fatil para pacientes com HCF, particularmente por aumentar os n\u00edveis de HDL-C, uma vez que tem sido menos relacionada \u00e0 alta freq\u00fc\u00eancia de miopatia. A niacina pode ser causa de flushings que podem ser reduzidos com o uso de aspirina. O efeito pode tamb\u00e9m ser minimizado com o uso de formas de libera\u00e7\u00e3o lenta (Niaspan). A niacina pode tamb\u00e9m elevar os n\u00edveis de glicemia e \u00e1cido \u00farico. Assim, os riscos e benef\u00edcios da associa\u00e7\u00e3o devem ser avaliados.<\/jats:p>","DOI":"10.1590\/s0004-27302006000200021","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T11:18:35Z","timestamp":1155122315000},"page":"344-359","source":"Crossref","is-referenced-by-count":8,"title":["Tratamento das dislipidemias: como e quando indicar a combina\u00e7\u00e3o de medicamentos hipolipemiantes"],"prefix":"10.1590","volume":"50","author":[{"given":"Isio","family":"Schulz","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0026-0495(76)90089-5","article-title":"Myocardial infarction in the familial forms of hypertriglyceridemia","volume":"25","author":"Brunzell JD","year":"1976","journal-title":"Metabolism","ISSN":"https:\/\/id.crossref.org\/issn\/0026-0495","issn-type":"print"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng1320","article-title":"Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1)","volume":"36","author":"Pajukanta P","year":"2004","journal-title":"Nat Genet","ISSN":"https:\/\/id.crossref.org\/issn\/1061-4036","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1194\/jlr.M500212-JLR200","article-title":"Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile","volume":"46","author":"van der Vleuten GM","year":"2005","journal-title":"J Lipid Res","ISSN":"https:\/\/id.crossref.org\/issn\/0022-2275","issn-type":"print"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001573-200311000-00012","article-title":"Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trials","volume":"18","author":"Xydakis AM","year":"2003","journal-title":"Curr Opin Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0268-4705","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/01.ATV.0000160612.18065.29","article-title":"Role of insulin resistance in familial combined hyperlipidemia","volume":"25","author":"Veerkamp MJ","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol","ISSN":"https:\/\/id.crossref.org\/issn\/1079-5642","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/ATVB.17v07.1465","article-title":"Non-obese patients with familial combined hyperlipidemia are insulin resistant compared with their non-affected relatives","volume":"17","author":"Bredie SJ","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol","ISSN":"https:\/\/id.crossref.org\/issn\/1079-5642","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.13.1.41","article-title":"Insulin resistance in familial and non-familial hypercholesterolemia","volume":"13","author":"Karhapaa P","year":"1993","journal-title":"Arterioscler Thromb","ISSN":"https:\/\/id.crossref.org\/issn\/1049-8834","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): Questions, quandaries, and paradoxes","volume":"40","author":"Mahley RW","year":"1999","journal-title":"J Lipid Res","ISSN":"https:\/\/id.crossref.org\/issn\/0022-2275","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.89.3.1333","article-title":"Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)","volume":"89","year":"1994","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy SM","year":"2004","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2004.02.013","article-title":"European Society of Cardiology; American Heart Association; American College of Cardiology: European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice","volume":"173","author":"De Backer G","year":"2004","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon CP","year":"2004","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies","volume":"79","author":"Gordon DJ","year":"1989","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study","volume":"62","author":"Gordon T","year":"1977","journal-title":"Am J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9343","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett AR","year":"2001","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ncpcardio0044","article-title":"Therapeutic approaches to raising plasma HDL-cholesterol levels","volume":"1","author":"Thompson MM","year":"2004","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S1047-2797(97)00130-0","article-title":"HDL cholesterol: trends in two southeastern New England communities, 1981-1993","volume":"8","author":"Derby CA","year":"1998","journal-title":"Ann Epidemiol","ISSN":"https:\/\/id.crossref.org\/issn\/1047-2797","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00041433-200406000-00006","article-title":"High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease","volume":"15","author":"Rohrer L","year":"2004","journal-title":"Curr Opin Lipidol","ISSN":"https:\/\/id.crossref.org\/issn\/0957-9672","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pcad.2004.04.007","article-title":"Comparative effects of lipid-lowering therapies","volume":"47","author":"Davidson MH","year":"2004","journal-title":"Prog Cardiovasc Dis","ISSN":"https:\/\/id.crossref.org\/issn\/0033-0620","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/01.mol.0000191913.16321.60","article-title":"Clinical implications for statin pleiotropy","volume":"16","author":"Liao, James K","year":"2005","journal-title":"Curr Opin Lipidol","ISSN":"https:\/\/id.crossref.org\/issn\/0957-9672","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0021-9150(00)00467-6","article-title":"Plasma lipids and cardiovascular risk: A POSCH report. Program on the surgical control of the hyperlipidemias","volume":"154","author":"Buchwald H","year":"2001","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones PH","year":"2003","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1210\/jc.2002-020370","article-title":"Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile","volume":"87","author":"Winkler K","year":"2002","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd J","year":"1995","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1161\/hc5001.100624","article-title":"Scandinavian Simvastatin Survival Study (4S) Group: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S","volume":"104","author":"Ballantyne CM","year":"2001","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref28","first-page":"213","article-title":"Rhabdomyolysis associated with lovastatin and erythromycin use","volume":"154","author":"Spach DH","year":"1991","journal-title":"West J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0093-0415","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1176\/ajp.153.3.311","article-title":"New antidepressants and the cytochrome P450 system","volume":"153","author":"Nemeroff CB","year":"1996","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","article-title":"Update: clinically significant cytochrome P-450 drug interactions","volume":"18","author":"Miehalase EL","year":"1998","journal-title":"Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/0277-0008","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/01.ATV.13.7.1110","article-title":"Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia","volume":"13","author":"Venkatesan S","year":"1993","journal-title":"Arterioscler Thromb","ISSN":"https:\/\/id.crossref.org\/issn\/1049-8834","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jn\/135.8.1829","article-title":"Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels?","volume":"135","author":"Varady KA","year":"2005","journal-title":"J Nutr","ISSN":"https:\/\/id.crossref.org\/issn\/0022-3166","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1258\/095646205774462805","article-title":"Antiretroviral therapy-induced hyperlipidemia","volume":"16","author":"Devi N","year":"2005","journal-title":"Int J STD AIDS","ISSN":"https:\/\/id.crossref.org\/issn\/0956-4624","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer JA","year":"2000","journal-title":"Drug Saf","ISSN":"https:\/\/id.crossref.org\/issn\/0114-5916","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson PD","year":"2003","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne CM","year":"2003","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","article-title":"Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"147","author":"Jamal SM","year":"2004","journal-title":"Am Heart J","ISSN":"https:\/\/id.crossref.org\/issn\/0002-8703","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis","volume":"36","author":"Omar MA","year":"2002","journal-title":"Ann Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199509073331003","article-title":"Effect of pravastatin on outcomes after cardiac transplantation","volume":"333","author":"Kobashigawa JA","year":"1995","journal-title":"N Engl J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.CIR.0000043241.32523.EE","article-title":"Simvastatin initiated early after heart transplantation: 8-year prospective experience","volume":"107","author":"Wenke K","year":"2003","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas H","year":"2003","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1210\/jc.2003-030388","article-title":"Medical management of hyperlipidemia\/dyslipidemia","volume":"88","author":"Kreisberg RA","year":"2003","journal-title":"J Clin Endocrinol Metab","ISSN":"https:\/\/id.crossref.org\/issn\/0021-972X","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: A review of its metabolism, pharmacokinetics and drug Interactions","volume":"44","author":"Kosoglou T","year":"2005","journal-title":"Clin Pharmacokinet","ISSN":"https:\/\/id.crossref.org\/issn\/0312-5963","issn-type":"print"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagne C","year":"2002","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson MH","year":"2002","journal-title":"J Am Coll Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0735-1097","issn-type":"print"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne C","year":"2003","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref47","first-page":"685","article-title":"Efficacy and safety of ezetimibe coadministered with pravastatina in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial","volume":"8","author":"Melani L","year":"2003","journal-title":"Eur Heart J","ISSN":"https:\/\/id.crossref.org\/issn\/0195-668X","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00128413-200414670-00030","article-title":"Ezetimibe complements fenofibrate in mixed hyperlipidaemia","volume":"1467","author":"Sullivan S","year":"2004","journal-title":"Inpharma Weekly","ISSN":"https:\/\/id.crossref.org\/issn\/1173-8324","issn-type":"print"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.atherosclerosis.2003.08.030","article-title":"Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia","volume":"171","author":"Westphal S","year":"2003","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0021-9150(97)00313-4","article-title":"Regulation of apo A-I gene expression by fibrates","volume":"137","author":"Staels B","year":"1998","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1172\/JCI118118","article-title":"Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferatoractivated receptor","volume":"96","author":"Vu-Dac N","year":"1995","journal-title":"Clin Invest"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1055\/s-0037-1614155","article-title":"Shortterm prognostic value of lipid measurements for coronary events in patients with angina pectoris","volume":"84","author":"Bolibar I","year":"2000","journal-title":"Thromb Haemost","ISSN":"https:\/\/id.crossref.org\/issn\/0340-6245","issn-type":"print"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"24N","DOI":"10.1016\/S0002-9149(01)02149-X","article-title":"Peroxisome proliferator-activated receptor a activation and high-density lipoprotein metabolism","volume":"88","author":"Fruchart JC","year":"2001","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/07853890310011969","article-title":"Contribution of apo-CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients","volume":"35","author":"Lemieux I","year":"2003","journal-title":"Ann Med","ISSN":"https:\/\/id.crossref.org\/issn\/0785-3890","issn-type":"print"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby P","year":"2002","journal-title":"Nature","ISSN":"https:\/\/id.crossref.org\/issn\/0028-0836","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"36703","DOI":"10.1074\/jbc.M004045200","article-title":"Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators","volume":"24;275","author":"Delerive P","year":"2000","journal-title":"J Biol Chem","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(03)00296-X","article-title":"Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: Relations with baseline lipid profiles","volume":"170","author":"Wang TD","year":"2003","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study","volume":"85","author":"Manninen V","year":"1992","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1001\/jama.285.12.1585","article-title":"VA-HIT Study Group: Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events","volume":"285","author":"Robins SJ","year":"2001","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention Study","volume":"102","year":"2000","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson CG","year":"1996","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol","volume":"96","author":"Frick MH","year":"1997","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study: A randomized study","volume":"357","year":"2001","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy SM","year":"2005","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001648-200109000-00017","article-title":"Lipid-lowering drugs and risk of myopathy: a population-based follow-up study","volume":"12","author":"Gaist D","year":"2001","journal-title":"Epidemiology","ISSN":"https:\/\/id.crossref.org\/issn\/1044-3983","issn-type":"print"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/ndt\/15.12.1993","article-title":"Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?","volume":"15","author":"Broeders N","year":"2000","journal-title":"Nephrol Dial Transplant","ISSN":"https:\/\/id.crossref.org\/issn\/0931-0509","issn-type":"print"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1159\/000064083","article-title":"Fenofibrate increases creatininemia by increasing metabolic production of creatinine","volume":"92","author":"Hottelart C","year":"2002","journal-title":"Nephron","ISSN":"https:\/\/id.crossref.org\/issn\/0028-2766","issn-type":"print"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.pharmtox.44.101802.121444","article-title":"Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs","volume":"45","author":"Shitara Y","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol","ISSN":"https:\/\/id.crossref.org\/issn\/0362-1642","issn-type":"print"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones PH","year":"2005","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham DA","year":"2004","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mcp.2002.128469","article-title":"Gemfibrozil greatly increases plasma concentrations of cerivastatin","volume":"72","author":"Backman JT","year":"2002","journal-title":"Clin Pharmacol Ther","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9236","issn-type":"print"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1345\/aph.10315","article-title":"Statin-fibrate combination therapy","volume":"35","author":"Shek A","year":"2001","journal-title":"Ann Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0021-9150(00)00379-8","article-title":"Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)","volume":"150","author":"Pauciullo P","year":"2000","journal-title":"Atherosclerosis","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9150","issn-type":"print"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2796.2000.00646.x","article-title":"Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety","volume":"247","author":"Gavish D","year":"2000","journal-title":"J Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0954-6820","issn-type":"print"},{"key":"ref75","first-page":"912","article-title":"Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease: Fibrate Consensus Group","volume":"81","author":"Fruchart JC","year":"1998","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"21K","DOI":"10.1016\/S0002-9149(02)02968-5","article-title":"Combination therapy for combined dyslipidemia","volume":"90","author":"Xydakis AM","year":"2002","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg A","year":"2000","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): A long-term study","volume":"82","author":"Capuzzi DM","year":"1998","journal-title":"Am J Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9149","issn-type":"print"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1172\/JCI107235","article-title":"Diurnal patterns of triglyceride, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis","volume":"52","author":"Schlierf G","year":"1973","journal-title":"J Clin Invest","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"291A","DOI":"10.1016\/S0735-1097(03)82366-5","article-title":"Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: Results from the Coronary Drug Project","volume":"39","author":"Canner PL","year":"2003","journal-title":"J Am Coll Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0735-1097","issn-type":"print"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes","volume":"162","author":"Grundy SM","year":"2002","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1185\/030079905X43677","article-title":"Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel","volume":"21","author":"Shepherd J","year":"2005","journal-title":"Curr Med Res Opin","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson LA","year":"1988","journal-title":"Acta Med Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-6101","issn-type":"print"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0735-1097(99)00585-9","article-title":"Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: A randomized, open-label, crossover study","volume":"35","author":"Zema MJ","year":"2000","journal-title":"J Am Coll Cardiol","ISSN":"https:\/\/id.crossref.org\/issn\/0735-1097","issn-type":"print"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprote\u00edna B","volume":"323","author":"Brown G","year":"1990","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown BG","year":"2001","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam MB","year":"2000","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v50n2\/29318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T11:08:34Z","timestamp":1736507314000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302006000200021&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0004-27302006000200021"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302006000200021","relation":{},"ISSN":["0004-2730"],"issn-type":[{"type":"electronic","value":"0004-2730"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}